Acadia (ACAD) PT Lifted to $26 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr boosted his price target on Buy-rated Acadia Pharmaceuticals (NASDAQ: ACAD) from $16 to $26 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE